Anemia in a cohort of HIV-infected Hispanics: prevalence, associated factors and impact on one-year mortality

BMC Research Notes

Robert F Hunter-Mellado¹  Yelitza Ruiz-Candelaria¹  Diana M Fernández-Santos²  Angel M Mayor²  Eduardo J Santiago-Rodríguez² 

[1] Cancer Research Center, Universidad Central del Caribe School of Medicine, Bayamón, 00960-6032 Puerto Rico;Retrovirus Research Center, Universidad Central del Caribe School of Medicine, 00960-6032 Bayamón, Puerto Rico

关键词: Puerto Rico;    Mortality;    Prevalence;    Hispanics;    HIV;    Anemia;   

Others  :  1131974
DOI  :  10.1186/1756-0500-7-439

 received in 2014-03-25, accepted in 2014-06-20,  发布年份 2014

【 摘 要 】

Background

Anemia occurs frequently in HIV-infected patients and has been associated with an increased risk of death in this population. For Hispanic subjects, information describing this blood disorder during HIV is scarce. Therefore, the present study examined data from a cohort of HIV-positive Hispanics to determine the prevalence of anemia, identify its associated factors, and evaluate its relationship with one-year mortality.

Methods

This study included 1,486 patients who enrolled between January, 2000 and December, 2010 in an HIV-cohort in Bayamón, Puerto Rico. Data were collected through personal interviews and medical record abstractions. To determine the factors independently associated with anemia, a multivariable logistic regression model was used. Kaplan-Meier and Cox proportional hazards models were also performed to estimate survival time and to predict death risk.

Results

The prevalence of anemia at enrollment was 41.5%. Factors independently associated with increased odds of anemia were: unemployment (OR = 2.02; 95% CI 1.45-2.79), CD4 count <200 cells/μL (OR = 2.66; 95% CI 1.94-3.66), HIV viral load ≥100,000 copies/mL (OR = 1.94; 95% CI 1.36-2.78), white blood cell count <4,000 cells/μL (OR = 2.42; 95% CI 1.78-3.28) and having clinical AIDS (OR = 2.39; 95% CI 1.39-4.09). Overweight (OR = 0.43; 95% CI 0.32-0.59) and obese (OR = 0.44; 95% CI 0.29-0.67) BMI’s were independently associated with reduced odds of anemia. Survival differed significantly by anemia status (log-rank test: p < 0.001). One-year mortality estimates were: 30.8%, 23.3%, 8.4% and 2.5%, for patients with severe, moderate, mild and no anemia, respectively. Having anemia at baseline was independently associated with an increased one-year mortality risk (severe anemia: HR = 9.06; 95% CI: 4.16-19.72; moderate anemia: HR = 6.51; 95% CI: 3.25-13.06; mild anemia: HR = 2.53; 95% CI: 1.35-4.74).

Conclusions

A high prevalence of anemia at enrollment was observed in this cohort of HIV-infected Hispanics. Unemployment and several adverse prognostic features of HIV infection were independently associated with this blood disorder. Anemia resulted to be the strongest predictor of one-year mortality, evidencing a dose–response effect. Further investigations are needed to evaluate whether recovering from anemia is associated with longer survival, and to identify the types of anemia affecting this particular group of HIV patients.

【 授权许可】

   
2014 Santiago-Rodríguez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Spivak JL, Bender BS, Quinn TC: Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med 1984, 77:224-228.
• [2]Zon LI, Arkin C, Groopman JE: Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 1987, 66:251-256.
• [3]Claster S: Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection. J Infect Dis 2002, 185(Suppl 2):105-109.
• [4]Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio MA, Ledergerber B, Lundgren JD: Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999, 13:943-950.
• [5]van der Werf MJ, van Benthem BH, van Ameijden EJ: Prevalence, incidence and risk factors of anaemia in HIV-positive and HIV-negative drug users. Addiction 2000, 95:383-392.
• [6]Levine AM, Berhane K, Masri-Lavine L, Sanchez M, Young M, Augenbraun M, Cohen M, Anastos K, Newman M, Gange SJ, Watts H: Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001, 26:28-35.
• [7]Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D, Human Immunodeficiency Virus Epidemiology Research Study Group: Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002, 34:260-266.
• [8]Mildvan D, Creagh T, Leitz G, Anemia Prevalence Study Group: Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 2007, 23:343-355.
• [9]Mugisha JO, Shafer LA, Van der Paal L, Mayanja BN, Eotu H, Hughes P, Whitworth JA, Grosskurth H: Anaemia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis and associated factors. Trop Med Int Health 2008, 13:788-794.
• [10]Subbaraman R, Devaleenal B, Selvamuthu P, Yepthomi T, Solomon SS, Mayer KH, Kumarasamy N: Factors associated with anaemia in HIV-infected individuals in southern India. Int J STD AIDS 2009, 20:489-492.
• [11]Dikshit B, Wanchu A, Sachdeva RK, Sharma A, Das R: Profile of hematological abnormalities of Indian HIV infected individuals. BMC Blood Disord 2009, 9:5.
• [12]De Santis GC, Brunetta DM, Vilar FC, Brandao RA, de Albernaz Muniz RZ, de Lima GM, Amorelli-Chacel ME, Covas DT, Machado AA: Hematological abnormalities in HIV-infected patients. Int J Infect Dis 2011, 15:e808-e811.
• [13]Mata-Marin JA, Gaytan-Martinez JE, Martinez-Martinez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M: Risk factors and correlates for anemia in HIV treatment-naive infected patients: a cross-sectional analytical study. BMC Res Notes 2010, 3:230.
• [14]Masaisa F, Gahutu JB, Mukiibi J, Delanghe J, Philippe J: Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. Am J Trop Med Hyg 2011, 84:456-460.
• [15]Moore RD: Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999, 29:44-49.
• [16]Volberding P: Consensus statement: anemia in HIV infection–current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther 2000, 22:1004-1020.
• [17]Sullivan P: Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection. J Infect Dis 2002, 185(Suppl 2):138-142.
• [18]Lundgren JD, Mocroft A: Anemia and survival in human immunodeficiency virus. Clin Infect Dis 2003, 37(Suppl 4):297-303.
• [19]Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW: Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301-308.
• [20]Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, Augenbraun M, Watts DH, Levine AM: Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2004, 37:1245-1252.
• [21]Moore RD, Keruly JC, Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:29-33.
• [22]Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, Anemia in HIV Working Group: Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004, 38:1454-1463.
• [23]Centers for Disease Control and Prevention: HIV Surveillance Report, 2011. 2013., 23http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ webcite
• [24]United States Census Bureau: 2010 Census Briefs: The Hispanic Population. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf webcite
• [25]Centers for Disease Control and Prevention: Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report, 2012. 2012., 17(no.4) http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental webcite
• [26]World Health Organization: Iron Deficiency Anaemia. Assessment, Prevention, and Control. A guide for Programme Managers. 2001. 2012. http://whqlibdoc.who.int/hq/2001/WHO_NHD_01.3.pdf webcite
• [27]Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN: Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008, 8:52.
• [28]Driscoll AK, Bernstein AB: Health and access to care among employed and unemployed adults: United States, 2009–2010. NCHS Data Brief 2012, 83:1-8.
• [29]Belperio PS, Rhew DC: Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004, 116(Suppl 7A):27-43.
• [30]Semba RD, Gray GE: Pathogenesis of anemia during human immunodeficiency virus infection. J Investig Med 2001, 49:225-239.
• [31]Alemu AW, Sebastian MS: Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action 2010., 3doi:10.3402/gha.v3i0.5398
• [32]Buskin SE, Sullivan PS: Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion 2004, 44:826-832.